Bernstein raised the firm’s price target on Insulet (PODD) to $335 from $315 following a strong quarter and an “impressive” outside-U.S. performance. The firm keeps an Outperform rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet’s Strong Q4 2024 Performance and Promising 2025 Outlook Drive Positive Rating and Price Target Increase
- Insulet’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- Robust Growth Prospects and Market Leadership Drive ‘Buy’ Rating for Insulet
- Insulet’s Financial Challenges: Navigating Pandemic Risks and Cybersecurity Threats
- Insulet’s Earnings Highlight Omnipod Success Amid Challenges